别名 CD334、FGFR-4、FGFR4 + [4] |
简介 Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and its lysosomal degradation. FGFR4 signaling is down-regulated by receptor internalization and degradation; MMP14 promotes internalization and degradation of FGFR4. Mutations that lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling. |
作用机制 FGFR1拮抗剂 [+3] |
在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2022-09-30 |
作用机制 FGFR1拮抗剂 [+3] |
在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2021-05-28 |
作用机制 FGFR1拮抗剂 [+3] |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2019-04-12 |
开始日期2026-01-13 |
申办/合作机构 |
开始日期2025-12-01 |
申办/合作机构 |
开始日期2025-08-25 |